Navamedic
Develops, produces, and commercializes medicines and related health products.
NAVA | OL
Overview
Corporate Details
- ISIN(s):
- NO0010205966
- LEI:
- 529900LKVQOR2SRUJU71
- Country:
- Norway
- Address:
- Henrik Ibsens gate 100, 0255 OSLO
- Website:
- https://navamedic.com/
- Sector:
- Wholesale and retail trade
- Industry:
- Other specialized wholesale
Description
Navamedic is a pharmaceutical company that develops, produces, and commercializes a diverse portfolio of medicines and related health products. The company's offerings include specialty pharmaceuticals, branded generics, and consumer health items. Its product portfolio addresses various medical needs, with treatments for conditions such as obesity, Parkinson's disorder, and inborn errors of metabolism, in addition to antibiotics. Serving as a reliable supplier and distribution partner, Navamedic provides high-quality products to hospitals and pharmacies, with a strong presence in the Nordic region and the Netherlands. The company focuses on improving patient outcomes through innovations, including advancements in personalized treatment for Parkinson's care.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2025-05-14 12:35 |
Navamedic ASA: Notice of Annual General Meeting
|
Norwegian | PDF • 2.0 MB | ||
| 2025-05-14 12:35 |
Navamedic ASA: Notice of Annual General Meeting
|
English | HTML • 931 bytes | ||
| 2025-05-05 08:56 |
Navamedic ASA launches Eroxon® in Denmark
|
English | HTML • 4.4 KB | ||
| 2025-04-30 17:42 |
Navamedic ASA: Annual Report 2024
|
English | ZIP • 13.3 MB | ||
| 2025-04-30 17:42 |
Navamedic ASA: Annual Report 2024
|
English | PDF • 3.9 MB | ||
| 2025-04-30 17:42 |
Navamedic ASA: Annual Report 2024
|
English | HTML • 2.0 KB | ||
| 2025-04-30 05:00 |
Navamedic Q1 2025: Sterk start på året og godt posisjonert for fremtidig vekst
|
English | PDF • 3.9 MB | ||
| 2025-04-30 05:00 |
Navamedic Q1 2025: Strong start of the year and well-positioned for future grow…
|
English | PDF • 3.9 MB | ||
| 2025-04-30 05:00 |
Navamedic Q1 2025: Sterk start på året og godt posisjonert for fremtidig vekst
|
Norwegian | HTML • 6.4 KB | ||
| 2025-04-30 05:00 |
Navamedic Q1 2025: Strong start of the year and well-positioned for future grow…
|
English | HTML • 6.3 KB | ||
| 2025-04-29 15:35 |
Navamedic ASA: Imdur® distribution agreement extended to 2032
|
English | HTML • 3.5 KB | ||
| 2025-04-28 14:44 |
Navamedic ASA: Conclusion received from the Norwegian Financial Supervisory Aut…
|
English | HTML • 3.6 KB | ||
| 2025-04-28 10:06 |
Navamedic ASA: Invitation to 2025 1st quarter presentation
|
English | HTML • 1.5 KB | ||
| 2025-04-10 06:50 |
Navamedic ASA: Navamedic has entered into an agreement in principle with Observ…
|
English | HTML • 2.8 KB | ||
| 2025-04-01 13:00 |
Navamedic Welcomes CHMP's Positive Review of Mysimba's Cardiovascular Safety
|
English | HTML • 3.5 KB |
Automate Your Workflow. Get a real-time feed of all Navamedic filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Navamedic
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Navamedic via our API.
Peer Companies
